Lasa Supergenerics Analysis

dividend

Pros

Cons

• Unable to evaluate Lasa Supergenerics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Lasa Supergenerics's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Lasa Supergenerics is profitable, therefore cash runway is not a concern.
• Lasa Supergenerics is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (28.1%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 1.6x debt.
• Lasa Supergenerics's cash and other short term assets cover its long term commitments.
• Lasa Supergenerics's level of debt (34.2%) compared to net worth is satisfactory (less than 40%).

Cons

• Lasa Supergenerics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
• Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Lasa Supergenerics board of directors is about average.
• Omkar's remuneration is about average for companies of similar size in India.
• Omkar's compensation has increased in line with Lasa Supergenerics recently becoming profitable.

Cons

misc

Pros

Cons

• Lasa Supergenerics is not covered by any analysts.
• Lasa Supergenerics has significant price volatility in the past 3 months.

past

Pros

Cons

• Lasa Supergenerics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
• Lasa Supergenerics used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Lasa Supergenerics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
• Lasa Supergenerics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
• Lasa Supergenerics has become profitable in the last year making it difficult to compare the IN Pharmaceuticals industry average.

value

Pros

• Lasa Supergenerics is good value based on assets compared to the IN Pharmaceuticals industry average.
• 540702 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
• 540702 outperformed the Market in India which returned -14.5% over the past year.
• BSE:540702 is up 21.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:540702 is up 21.1% outperforming the market in India which returned 8% over the past month.

Cons

• Lasa Supergenerics is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
• Lasa Supergenerics is overvalued based on earnings compared to the India market.